The safety of vedolizumab for ulcerative colitis and Crohn's disease-Reference-Cited by-同舟云学术

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Published:2016-02-18 Issue:5 Volume:66 Page:839-851
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Colombel Jean-Frédéric,Sands Bruce E,Rutgeerts Paul,Sandborn William,Danese Silvio,D'Haens Geert,Panaccione Remo,Loftus Edward V,Sankoh Serap,Fox Irving,Parikh Asit,Milch Catherine,Abhyankar Brihad,Feagan Brian G

Publisher

BMJ

Subject

Gastroenterology

Reference35 articles.

1. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects;Mosli;Drugs,2014

2. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases;Soler;J Pharmacol Exp Ther,2009

3. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease;Garnock-Jones;BioDrugs,2015

4. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med,2013

5. Vedolizumab as induction and maintenance therapy for Crohn's disease;Sandborn;N Engl J Med,2013

Cited by 666 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Immediate Hypersensitivity Reactions to Biologic Drugs in Children with Inflammatory Bowel Diseases;International Archives of Allergy and Immunology;2024-09-04

3. Integrins and NAFLD-associated liver diseases: clinical associations, pathophysiological mechanisms and pharmacological implications;Acta Biochimica et Biophysica Sinica;2024-09-01

4. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins;The Korean Journal of Gastroenterology;2024-08-25

5. Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database;Intestinal Research;2024-08-19